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Abstract
Objective: The current study aimed at comparing the efficacy of dexmedetomidine and magnesium sulfate to control blood pres-
sure (BP) during rhinoplasty and the resultant effects on the quality of surgical field in terms of bleeding and visibility.
Methods: The current randomized, prospective, double-blind study was conducted on 60 patients aged 18 to 50 years classified as
ASA (American Society of Anesthesiologists) physical status I who were candidates for rhinoplasty. Patients were randomly divided
into 2 groups: (1) group Dex, received 1 µg/kg dexmedetomidine in 10 minutes before induction of anesthesia, followed by 0.4 - 0.6
µg/kg/hour during the maintenance of anesthesia, and (2) group Mg, received 40 mg/kg in 10 minutes before anesthesia induction
followed by 10 - 15 mg/kg/hour during anesthesia maintenance. In both groups, the goal was to achieve a mean arterial pressure
(MAP) of 60 - 70 mmHg. Hemodynamic variables, anesthetic, opioid, muscle relaxant requirements, and surgical field condition
were recorded. Sedation score, time to reach modified Aldrete score≥ 9, and adverse effects including nausea and vomiting (N&V)
and shivering were recorded.
Results: Controlled hypotension was achieved in both groups. There was no significant difference in MAP between the groups, but
heart rate (HR) was significantly lower in the Dex group (P < 0.001), compared with that of the Mg group. Bleeding score was lower
(P < 0.001) and surgeon’s satisfaction score was higher (P < 0.001) in the Dex group. More patients required fentanyl (P < 0.001) or
nitroglycerin (P < 0.001) and the mean fentanyl (P = 0.005) or nitroglycerin (P < 0.001) required doses were higher in the Mg group.
Patients in the Dex group required more frequent administration of cisatracurium (P = 0.004). Five patients in the Dex group versus
no patients in the Mg group received atropine (P = 0.023). Ramsay sedation score and time to reach modified Aldrete score≥ 9 were
significantly higher in the Dex group (P < 0.001 and P < 0.001, respectively). The incidence rate of N&V and shivering were similar
in both groups.
Conclusion: Dexmedetomidine was more effective than magnesium to achieve controlled hypotension, and provide a favorable
surgical field condition. However, dexmedetomidine also heightened the risk of induced bradycardia and prolonged sedation.
These are 2 important points to consider when applying this drug as a hypotensive agent during operation.
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1. Background
Rhinoplasty is still one of the most popular surgical
procedures in the world (1) and bleeding during opera-
tion through the blood rich nasal mucosa obscures surgi-
cal field visibility and sometimes results in suboptimal sur-
gical outcome. Application of the controlled hypotension
improves operative field visibility and decreases the dura-
tion of surgery (2), total blood loss (3, 4), and rate of post-
operative edema and ecchymosis (2, 5).
Many different drugs are tried to achieve controlled hy-
potension conventionally defined as a reduction of the sys-
tolic blood pressure (BP) to 80 - 90 mmHg, a reduction of
mean arterial pressure (MAP) to 50 - 65 mmHg or a 30% re-
duction of baseline MAP (6, 7).
Dexmedetomidine is a highly selective α2 adrenergic
receptor agonist (selectivity ratio for α2: α1 is 1600:1) (8).
The sympatholytic effect of this α2 agonist made it at-
tractive to be used as a hypotensive drug (9, 10) during
the surgery. It results in a decrease in heart rate (HR)
and cardiac output accordingly (11), whereas no decrease
in stroke volume occurs unless the plasma concentrates
reaches above 5.1 µg/mL (12). This drug also has sedative
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(12), amnesic, anxiolytic, hypnotic, and analgesic (13, 14) ef-
fects with minimal changes in respiratory variables (12, 15).
Furthermore, it reduces postoperative nausea (13), vomit-
ing (16), and shivering (17, 18). It also reduces delirium in
patients after cardiac surgery (19).
Magnesium sulfate is studied as a hypotensive agent
for several years in different surgical procedures (20-22). It
decreases anesthetic, analgesic, and muscle relaxant (20)
requirements as well as the incidence of nausea, vomiting,
and shivering (21-23). Magnesium affects the regulation of
sympathetic tone and BP through blocking N-type and par-
tially L-type calcium channels, and as a result inhibits nore-
pinephrine release (24). Magnesium acts as an N-methyl-
D-aspartate (NMDA) receptor antagonist (25); therefore, it
reduces analgesic and anesthetic requirements.
Although previous studies demonstrated the ability
of the above mentioned drugs to provide controlled hy-
potension during operation, few studies compared them
together specifically in rhinoplasty. The similar clinical
characteristics of dexmedetomidine and magnesium sul-
fate beside the stable hemodynamic response to anesthe-
sia and a significant decrease in HR following the admin-
istration of dexmedetomidine led to the design of the cur-
rent study to recommend a more effective drug with fewer
side effects. The current study aimed at comparing the effi-
cacy of dexmedetomidine and magnesium sulfate to con-
trol BP during rhinoplasty and the resultant effects on the
quality of surgical field in terms of bleeding and visibility.
Recovery profile and complications were also compared.
2. Materials and Methods
The current randomized, prospective, double-blind
study was conducted at a university hospital (Firoozgar
Hospital affiliated to Iran University of Medical Sciences,
Tehran, Iran), from May 2016 to February 2017. After obtain-
ing the study protocol approval from the Ethics Committee
of the university (code: IR. IUMS.REC 1395.138340) as well as
informed consent from the subjects, 60 patients aged 18 to
50 years with ASA (American society of anesthesiologists)
class I who were candidates for rhinoplasty were enrolled.
Patients were randomly divided into 2 groups to receive ei-
ther dexmedetomidine (Dex) or magnesium sulfate (Mg)
as hypotensive agent during the surgery. Patients with re-
vision rhinoplasty, known allergy to the study drugs, opi-
oid abuse, bleeding disorder, and the ones using contra-
ceptives were excluded from the study.
In the operating room, electrocardiogram (ECG), BP
(systolic, diastolic, MAP), HR, peripheral oxygen saturation
(SPO2), end-tidal carbon dioxide (ETCO2), and bispectral in-
dex (BISPECTRAL VISTA monitoring system; Covedian com-
pany, USA) were monitored. Neuromuscular blockade was
also measured with TOF-Watch (TOF watch SX, Organon,
Ireland). A crystalloid solution at a rate of 4 mL/kg/hour
was started and continued through the surgery. In the
DEX group, a loading dose of 1 µg/kg dexmedetomidine
(Precedex, 200 µg/2mL, Hospira , USA) diluted in 50 mL of
saline 0.9% was infused intravenously in 10 minutes before
induction of anesthesia followed by continuous infusion
of 0.4-0.6 µg/kg/hour during the maintenance of anesthe-
sia. In the Mg group, a loading dose of 40 mg/kg of mag-
nesium sulfate (50% solution, Pasteur Institute of Iran) di-
luted in 50 mL of 0.9% saline, was infused intravenously
in 10 minutes before induction of anesthesia followed by
continuous infusion of 10-15 mg/kg/hour during the oper-
ation. Anesthetic management as well as data collection
and recording were performed by the same anesthesiol-
ogist blinded to the drugs applied to the groups. Both
the study drugs were prepared by another person in a way
that the rate of infusion/ body weight was similar in both
groups. In order to exclude interpersonal variation in eval-
uation of surgical field, all the operations were performed
by the same surgeon who also evaluated the surgical field.
Patients were preoxygenated with 100% oxygen and
premedicated with 3 µg/kg of fentanyl. Anesthesia was
induced with propofol 2.5 mg/kg and cisatracurium 0.15
mg/kg. Tracheal intubation was performed when post
tetanic stimulation was zero. Oropharyngeal pack was
used and patients were positioned in 20° reverse Trende-
lenburg. Anesthesia was maintained by the inspiration of
0.8% - 1.5% isoflurane at fresh gas flow with 50% nitrous ox-
ide/oxygen mixture to keep bispectral index (BIS) values in
a range of 40 - 60. Muscle relaxation was maintained with
intermittent bolus administration of cisatracurium 0.02
mg/kg when more than 2 twitches were depicted by TOF
watch. Patients were mechanically ventilated; respiratory
rate and tidal volume were adjusted to provide a SpO2 level
of more than 95% and end-tidal carbon dioxide level of 30
- 35 mmHg.
Five to ten milliliters of a solution containing 2% li-
docaine and epinephrine 1:100,000 were administered
locally in subperichondrial and supraperiosteal planes.
Adrenaline cottonoids 1:1000 were also used for mucosal
decongestant purposes at surgical sites.
In both groups, the goal was to achieve a mean arte-
rial pressure of 60-70 mmHg. Isoflurane was adjusted to
keep BIS values in the range of 40-60. If BP increased higher
than desired level and HR also increased to more than 20%
of preoperative value in spite of acceptable BIS values, 1
µg/kg of fentanyl was administered intravenously to treat
inadequate analgesia. If only BP was higher than desired
level, a bolus of nitroglycerine 50µg was administered in-
travenously. If BP decreased lower than the desired level,
the rate of drug infusion was reduced in the current study.
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If BP did not reach the desired value, a bolus of ephedrine 5
mg was administered intravenously. In case of occurrence
of bradycardia, if it was accompanied by a MAP less than
55 mmHg, a bolus of atropine 10 µg/kg was administered
intravenously, but if MAP was in the acceptable range, in-
fusion of the drug was discontinued and atropine admin-
istration was delayed till the HR got back to its normal val-
ues. The number of patients received fentanyl, nitroglyc-
erin, atropine, or ephedrine as well as the total doses re-
quired in each group were recorded.
A bolus of alfentanil 8 µ/kg was administered before
the performance of osteotomy. All the drugs were discon-
tinued 10 minutes before the end of operation. Muscle re-
laxation was reversed with neostigmine 40 µg/kg and at-
ropine 20µg/kg at the 4th twitch of TOF count. Patients
were extubated when they were awake, TOF ratio more
than 90%, and then transferred to the Post Anesthesia Care
Unit (PACU).
HR, BP (systolic, diastolic, and MAP), and BIS values
were recorded on arrival to the operating room, before in-
duction of anesthesia, after intubation, and then 5, 10, and
15 minutes after intubation and every 15 minutes there-
after. TOF and end-tidal CO2 values were added to the
abovementioned recordings after induction of anesthesia.
The data were also recorded 2 minutes after epinephrine
infiltration, at the end of surgery, after extubation, and ev-
ery 15 minutes during the PACU stay. Isoflurane inhalation
by fresh gas flow was recorded every 15 minutes and times
required to repeat muscle relaxant administration were
recorded.
The number of patients received fentanyl, nitroglycer-
ine, atropine, or ephedrine as well as mean dose require-
ment in each group were recorded. Time of discontin-
uation of the anesthetic drugs and tracheal extubation
(named the extubation time) was recorded as well.
Surgical field was assessed by the surgeon in terms of
bleeding and visibility using a 6-option Liker-scale scale
adapted from Fromme el al. (26): 0 = no bleeding; 1 = mi-
nor bleeding, but no aspiration required; 2 = minor bleed-
ing, aspiration required; 3 = minor bleeding, frequent aspi-
ration required; 4 = moderate bleeding, visible only with
aspiration; 5 = severe bleeding, continuous aspiration re-
quired. Surgeon’s satisfaction with the operative field was
rated using a 4 -option Likert scale at the end of surgery: 1
= bad, 2 = moderate, 3 = good, and 4 = excellent.
Postoperative sedation was evaluated using the Ram-
say sedation score (27) at 15, 30, 45, and 60 minutes after tra-
cheal extubation. Postoperative recovery was assessed by
the modified Aldrete score (28), and time needed to reach
score≥ 9 was defined as the recovery period. Adverse ef-
fects such as bradycardia, shivering, nausea, and vomiting
were recorded.
2.1. Statistical Analysis
Data were analyzed using IBM SPSS version 24.0 (Ar-
monk, NY: IBM Corp). Normal distribution of data was
tested by the Kolmogorov-Smirnov test. The student t test
and the Mann-Whitney U test were used to compare nu-
merical variables; Chi-square and the Fisher exact tests
were used to compare categorical variables between the 2
study groups. MAP and HR were compared between the
study groups using 2-way analysis of variance for repeated
measurements. Results throughout the text, tables, and
figures are expressed as mean ± SD. Two-sided P value <
0.05 was considered statically significant. Sample size was
estimated based on the surgeon’s satisfaction score de-
rived from the pilot study on 20 patients (10 in each group).
For instance, surgeon’s satisfaction scores 1 - 2 were catego-
rized as “low satisfaction” and scores 3 - 4 were categorized
as ‘high satisfaction”. High satisfaction rates in the Dex and
Mg groups were 60% and 20%, respectively. Considering
type 1 error 0.05 and type 2 error 0.2, a minimum of 28 pa-
tients were needed in each group.
3. Results
A total of 60 patients were enrolled in the study of
which 57 completed the study. Two patients in the Dex
group were excluded, 1 because of refusing to participate in
the study and the other due to drug abuse. One patient in
the Mg group had hypothyroidism discovered in the oper-
ating room. Patients in both groups were matched by age,
weight, gender (Table 1), duration of surgery, and isoflu-
rane consumption (Table 2). Patients in the Dex group re-
quired more frequent administration of cisatracurium (P
= 0.004).
MAP was achieved within the desired range in both
groups. There was no significant difference between the 2
groups in terms of the mean baseline HR and MAP. HR dur-
ing operation (Figure 1) was significantly lower in the Dex
group (P < 0.001), compared with that of the Mg group. Al-
though mean MAP during operation (Figure 2) in the Dex
and Mg groups was 68.21 ± 3.52 and 70.58 ± 5.35 mmHg,
respectively, the difference was statistically insignificant (P
= 0.054). MAP after epinephrine administration was also
similar in both the study groups.
MAP and HR values at tracheal extubation and during
the stay at PACU were higher in the Mg group, compared
with those of the Dex group (P = 0.018 and P < 0.001, re-
spectively).
More patients required fentanyl (P < 0.001) and nitro-
glycerin (P < 0.001) in the Mg group than the Dex group.
Means of fentanyl dose (P < 0.005) and nitroglycerine dose
(P < 0.001) required in the Mg group were higher as well
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(Table 2). None of the patients in the study groups required
ephedrine administration. Bradycardia occurred in 7 pa-
tients in the Dex group and 1 patient in the Mg group.
Five patients in the Dex group received atropine. The dif-
ferences in the incidence of bradycardia and atropine re-
quirement were significant between the groups (P = 0.011
and P = 0.023, respectively) (Table 2). Bleeding score (Table
3) was significantly lower (P < 0.001), and surgeon’s satis-
faction score was significantly higher (P < 0.001) in the Dex
group than in the Mg group.
Extubation time was similar in both the study groups.
The Ramsay sedation score (Table 4) at 15, 30, 45, and 60
minutes was significantly higher in the Dex group, com-
pared with that of the Mg group (P < 0.001). Time to reach
Aldrete score≥ 9 was also significantly higher in the Dex
group, compared with the Mg group (P < 0.001) (Table 4).
Two patients in the Mg group had nausea and vomiting
and 1 patient in the same group had shivering, but the dif-
ference between the groups was insignificant.
Table 1. Demographic Data
Dex Group (N =
28)
Mg Group (N = 29) P Value
Age, year 26.28± 9.48 25.55± 7.1 0.682
Gender,
female/male
21.7 25.4 0.331
Weight, kg 66.42± 12.95 68± 10.5 0.144
Data are expressed as mean± standard deviation (SD) or number of patients
4. Discussion
According to the conventional standards of controlled
hypotension employed in many studies (6, 7), it is intended
to maintain MAP at 50 - 60 mmHg. Edram et al., (29) as-
sessed regional cerebral oxygen saturation using infrared
spectroscopy during controlled hypotension in patients
undergoing rhinoplasty. They reported that when MAP de-
creased to 50 - 60 mmHg, cerebral desaturation occurred
in 10% of the patients. Based on their results, to prevent the
occurrence of undistinguished cerebral hypoxia, it was de-
cided to maintain the MAP in 60 - 70 mmHg in the current
study.
The current study results suggest that controlled hy-
potension was achieved in both groups and despite the
lower mean values of MAP in the Dex group, the difference
was not statistically significant between the study groups;
but the operative field condition was more favorable in the
Dex group than the Mg group in terms of bleeding and vis-
ibility. Moreover, BP control was easier in the Dex group,
Table 2. Intraoperative Data and Adverse Effects
Dex Group (N =
28)
Mg Group (N = 29) P Value
Duration of
surgery, min
144± 40.8 133.2± 45.6 0.35
Isoflurane dose
(%)
0.817± 0.34 0.95± 0.18 0.074
Times of
intermittent
cisatracurium
required
1.71± 1.27 0.82± 0.84 0.004
Nitroglycerin
requirement,µg
8.92± 38.61 134.48± 165.88 < 0.001
Nitroglycerin
requirement, no.
of pts.
3 15 < 0.001
Fentanyl
requirement,
µ/(kg)
0.14± 0.44 0.62± 0.14 0.005
Fentanyl
requirement, no.
of pts.
2 13 < 0.001
Atropine
requirement, no.
of pts.
5 0 0.023
Extubation time,
min
14.1± 5.61 12.41± 3.92 0.27
Nausea, no. of
pts.
0 2 0.25
shivering, no. of
pts.
0 1 0.51
Data are expressed as mean± SD or number of patients, no. of pts.
that is, the number of patients that required nitroglycer-
ine or fentanyl administration was lower in the Dex group.
Furthermore, mean dose of nitroglycerine and fentanyl re-
quired in the Dex group was lower than those of the Mg
group.
In several studies, dexmedetomidine was compared
with esmolol or remifentanil as a hypotensive drug, and
the results were inconsistent. In some studies, dexmedeto-
midine produced lower HRs and BP as well as better
surgical field condition, compared with esmolol (30, 31),
whereas in other studies these effects of dexmedetomidine
were similar to those of esmolol (32). It was also demon-
strated in some studies that dexmedetomidine was as ef-
fective as remifentanil to produce controlled hypotension
with similar hemodynamic properties (33, 34), but in an-
other study, it was concluded that dexmedetomidine was
less effective than remifentanil to achieve controlled hy-
potension and good surgical field exposure (35). Mag-
nesium was also compared with remifentanil in 2 stud-
ies (21, 36). Both drugs were similar in terms of provid-
4 Anesth Pain Med. 2017; 7(6):e64032.
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Figure 1. Heart Rate of Participants in the Dexmedetomidine (Dex; Blue Diamonds) and Magnesium Sulfate (Mg; Red Squares) Groups; Epinephrine Reading After Topical
Epinephrine administration
Dex
Sulfate
120
110
100
90
80
70
60
50
40
Ba
se
lin
e
Pr
e-i
nd
uc
tio
n
Po
st-
in
tu
ba
tio
n
5 m
in
10
 m
in
15
 m
in
Ep
in
ep
hr
in
e
30
 m
in
45
 m
in
60
 m
in
75
 m
in
90
 m
in
10
5 m
in
12
0 
m
in
135
 m
in
15
0 
m
in
16
5 m
in
Af
te
r-E
xt
ub
at
io
n
15
 m
in
 Af
te
r E
xt
ub
at
io
n
30
 m
in
 Af
te
r E
xt
ub
at
io
n
45
 m
in
 Af
te
r E
xt
ub
at
io
n
M
ea
n
 A
rt
er
ia
l P
re
ss
u
re
Figure 2. Mean Arterial Pressure of Participants in the Dexmedetomidine (Dex; Blue Diamonds) and Magnesium Sulfate (Mg; Red Squares) Groups; Epinephrine Reading After
Topical Epinephrine Administration
ing controlled hypotension; lower HRs and MAP were re-
ported with magnesium in a study, while the other one (36)
reported similar hemodynamic properties in the study
groups.
The current study results were consistent with previ-
ous studies on dexmedetomidine. Bayram et al., (37) com-
pared the hypotensive effects of dexmedetomidine and
magnesium sulfate during functional endoscopic sinus
surgery. They reported lower bleeding and higher sur-
geon’s satisfaction scores with dexmedetomidine admin-
istration in addition to significantly lower HRs and MAP
during the operation using this drug compared with those
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Table 3. Operation Field Data
Bleeding
Scorea
Dex Group (N =
28) (%)
Mg Group (N =
29) (%)
P Value
0 1 (3.6) 0 (0)
0.001
1 3 (10.7) 0 (0)
2 14 (50) 6 (20.7)
3 7 (25) 4 (13.8)
4 2 (7.1) 12 (41.4)
5 1 (3.6) 7 (24.1)
Surgeon’s
satisfaction
scoreb
1 1 (3.6) 6 (20.7)
0.001
2 5 (17.9) 14 (48.3)
3 8 (28.6) 6 (20.7)
4 14 (50) 3 (10.3)
Data are expressed as number of patients and, in parenthesis, the percentage
in each group
a Bleeding score: 0 = no bleeding; 1 = slight bleeding, no aspiration required; 2
= minor bleeding, aspiration required; 3 = minor bleeding, frequent aspiration
required; 4 = moderate bleeding, visible only with aspiration; 5 = severe bleed-
ing, continuous aspiration required
b Surgeon’s satisfaction score: 1 = bad; 2 = moderate, 3 = good; 4 = excellent
Table 4. Recovery Data
Dex Group (N =
28)
Mg Group (N = 29) P Value
Time to reach
modified
alderete score
(28)≥ 9, min
22.53± 3.56 15± 2.89 < 0.001
The ramsey
scorea at 15 min
after surgery
4.71± 0.46 2.4± 0.5 < 0.001
At 30 min after
surgery
4.32± 0.66 2.24± 0.43 < 0.001
At 45 min after
surgery
4.17± 0.66 2.1± 0.3 < 0.001
At 60 min after
surgery
3.07± 0.71 2± 0 < 0.001
Data are expressed as mean± SD or number of patients
aThe Ramsay sedation score: 1 = anxious, agitated or restless; 2 = cooperative,
oriented and tranquil; 3 = responsive to commands; 4 = asleep, but with brisk
response to light glabellar tap or light auditory stimulus; 5 = asleep, sluggish
response to glabellar tap or auditory stimulus; 6 = asleep, no response
of magnesium sulfate. They used the same drug dose regi-
mens as used in the current study.
In the current study, patients in the Dex group had
lower HRs than the ones in the Mg group during the opera-
tion, which may explain the better surgical field condition
in the Dex group. Some studies (38, 39) reported that by de-
creasing the HR, a better operative field condition was pro-
vided. Moreover, as Sieskiewicz et al. found (40), to provide
a better surgical condition, there was no need to decrease
MAP to the risky low levels if HR was maintained as low as
60 beat/minute. Dexmedetomidine induces bradycardia
through its action on α2-agonist receptors (8). Although
magnesium reduces HR (20) probably through inhibition
of norepinephrine release (24), it seems that the decrease
in HR is more prominent with dexmedetomidine rather
than magnesium. In the study by Byram et al. (37), signifi-
cantly slower HRs during anesthesia in the dexmedetomi-
dine group was also reported.
Lower HRs in the Dex group might be one of the rea-
sons that better surgical field condition was achieved in
this group. However, bradycardia occurred in 7 patients in
the Dex group, 5 of which needed atropine administration,
while bradycardia occurred just in 1 patient of Mg group
and no atropine was required in this group. In the study
by Byram et al. (37), although the incidence of bradycardia
(i e, HR decrease more than 20% of initial rate) was similar
in both groups, it occurred in 4 patients in the Dex group
versus 1 patient in the Mg group. Moreover, there are some
case reports of cardiac arrest (41-43) following dexmedeto-
midine administration, which should be considered when
choosing this drug as a hypotensive agent during opera-
tion.
In the current study, bleeding score was lower and
surgeon’s satisfaction score was higher in the Dex group
rather than those of the Mg group. Besides the decrease
in BP and HR by dexmedetomidine administration, pe-
ripheral vasoconstriction might be another reason for less
bleeding and better quality of surgical field provided by
this drug. Lawrence et al., (44) reported that dexmedetomi-
dine decreased organ blood flow in dogs, with the largest
decrease in the skin (up to 90%). This vasoconstriction may
be achieved through the known vasoconstrictive effect of
dexmedetomidine on postsynaptic α2 adrenoceptors lo-
cated in peripheral blood vessels (45).
In the current study, less opioid was required in the
DEX group than the Mg group. Many studies showed that
dexmedetomidine reduced opioid (9, 10, 13, 14) require-
ments during and after the operation. Dexmedetomidine
exerts its analgesic effect throughα2 receptors in the locus
coeruleus and spinal cord (46). Magnesium acts as NMDA
receptor antagonist (25). Different results were reported
about the analgesic effect of magnesium. In the study by
Cizmeci et al. (47), magnesium did not reduce analgesic re-
quirements during anesthesia, whereas in a meta-analysis
by Albercht E et al. (48), it was concluded that magne-
sium sulfate reduced postoperative pain. Results of the
current study showed that dexmedetomidine administra-
tion decreased opioid requirement with a greater extent
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than magnesium administration. Though it seems that
dexmedetomidine has stronger analgesic effect than mag-
nesium.
Previous studies showed that magnesium administra-
tion enhanced neuromuscular blocking action of muscle
relaxants (47-49). Magnesium acts as a calcium channel
blocker at presynaptic nerve terminals, thus it causes a de-
crease in presynaptic acetylcholine release at the motor
endplate and has some advantages for general and neurax-
ial anesthesia (50, 51). The results of the current study were
consistent with those of previous studies. The requirement
for cisatracurium was less in the Mg group than the Dex
group, while duration of anesthesia was the same in the 2
groups.
In the current study, patients in Dex group were more
sedated at all recording times in the PACU and the time du-
ration to reach modified Aldrete score≥ 9 was longer com-
pared with those of the Mg group.
Byram et al. (37) reported contradictory results. In
their study, the duration to reach modified Aldrete score
≥ 9 was shorter with dexmedetomidine rather than mag-
nesium. Magnesium decreased anesthetic requirements
in some studies (20). In the studies comparing intra-
venous dexmedetomidine and intravenous remifentanil
administration as a hypotensive agent during operation,
it was observed that patients receiving dexmedetomidine
were more sedated (32) (using different scoring system),
and the time needed to reach modified Aldrete score ≥
9 was longer (33) than those of the ones that received
remifentanil. Similarly, sedation score was higher when
dexmedetomidine was administered to induce hypoten-
sion during functional endoscopic sinus surgery, com-
pared with that of esmolol (29).
4.1. Conclusion
Dexmedetomidine was more effective than magne-
sium to achieve controlled hypotension, and provide a fa-
vorable surgical field condition. However, this drug also
comes with a heightened risk of induced bradycardia and
prolonged sedation. These are 2 important points to con-
sider when choosing this drug as a hypotensive agent dur-
ing operation.
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